- Post-Inhibitex, BMS pins down hepatitis C options
- Vertex see-saws on new HCV combo partners, disappointing 3Q
- Roche deal gives new anti-HCV to China start-up
- AASDL 2012: A shift to direction action in hepatitis C?
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.